Metabolic syndrome is an important long term complication in chronic asymptomatic HIV-infected subjects under highly active antiretroviral therapy (HAART), because it can contribute to morbidity and mortality via cardiovascular disease (CVD). Therefore, a predictive marker for early detection of metabolic syndrome may be necessary to prevent CVD in HIV-infected subjects. Retinol-binding protein-4 (RBP-4) has been shown to be associated with metabolic syndrome in various non-HIV-infected populations. We performed a cross-sectional study to evaluate whether serum RBP-4 levels are correlated with metabolic syndrome in HIVinfected subjects receiving HAART. In total, 98 HIV-infected Koreans who had been receiving HAART for at least 6 months were prospectively enrolled. Metabolic syndrome was diagnosed according to the Adult Treatment Panel III criteria, and serum RBP-4 concentrations were measured using human RBP-4 sandwich enzyme-linked immunosorbent assay. Serum RBP-4 levels were significantly higher in HIV-infected subjects receiving HAART with metabolic syndrome (n=33, 33.9±7.7 μg/mL) than in those without it (n=65, 29.9±7.2 μg/mL) (p=0.012). In multivariate linear regression analysis, the number of components of metabolic syndrome presented and waist circumference were independently, significantly correlated with RBP-4 (p=0.018 and 0.030, respectively). In conclusion, we revealed a strong correlation between RBP-4 and the number of components of metabolic syndrome in HIV-infected subjects receiving HAART. nosis was based on the clinical definition set by the US Division of AIDS adverse events (2004 version), in addition to a standardized LD-specific physical examination conducted by a single clinician and a previously described LDspecific questionnaire completed by the patient. 13 BP, height, weight, and waist and hip circumference were measured. Waist-to-hip ratio (WHR) and body mass index (BMI) were also calculated.
We obtained blood samples following a 12-hour overnight fast. Plasma glucose, total cholesterol, triglyceride, HDL-cholesterol, peripheral blood CD4+ T lymphocyte counts, and plasma HIV-RNA were measured using standard laboratory methods. Low-density lipoprotein-cholesterol was calculated using the Friedewald formula, 14 except in patients with TG levels higher than 400 mg/dL.
Serum RBP-4 concentrations were measured using the commercially available human RBP-4 sandwich enzymelinked immunosorbent assay kit (Immunodiagnostik AG, Bensheim, Germany). The assay was conducted according to the manufacturer's instructions. The inter-assay and intraassay variations were 9.8% and 5%, respectively.
All statistical analyses were performed using the SPSS MetSyn, metabolic syndrome; BP, blood pressure; WHR, waist-to-hip ratio; BMI, body mass index; HAART, highly active antiretroviral therapy; NI, not included in the multivariate model; EX, excluded variables in the multivariate model; RBP-4, retinol-binding protein-4; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein. *Independent variables included in the multivariate model were age, BMI and all variables with a p-value of less than 0.10 on an age and BMI-adjusted partial correlation analysis. In this model, the cut-off level of the probability of F value used for the entry or removal of successively entered variables was 0.05 and 0.10, respectively. † Logarithmic transformation was performed because of a skewed distribution.
ed with a higher risk of MetSyn in HIV-infected subjects receiving HAART. We also found a strong correlation between serum RBP-4 levels and the number of components of MetSyn, in particular, its key components, including TG and waist circumference. This significant correlation was not attenuated after adjustment for age and BMI, which are known to be related to the prevalence of MetSyn. 18, 19 We also noted an increased prevalence of LD in HIV-infected subjects with MetSyn. These findings suggest a potential role for serum RBP-4 as a diagnostic marker for early detection of metabolic complications in HIV-infected subjects receiving HAART. To our knowledge, this is the first study to evaluate the relationship between serum RBP-4 levels and the presence of MetSyn in HIV-infected subjects. However, we did not compare serum RBP-4 levels between HIVinfected subjects receiving HAART without MetSyn and non-HIV-infected healthy individuals without MetSyn, in this study. In addition, we did not measure serum RBP-4 levels in the HIV-infected individuals who have never received HAART (treatment-naïve individuals). Therefore, there may be the possibility that neither HIV infection itself nor HAART have any impact on the association between RBP-4 and MetSyn. Further study with the aforementioned study design and a larger sample set is needed to evaluate whether serum RBP-4 levels are useful as diagnostic markers for MetSyn and/or predictive factors for the development of MetSyn or CVD in HIV-infected subjects receiving HAART, as well as to reveal the exact mechanism or causality for the relationship between RBP-4 and MetSyn in HIV-infected subjects. Because serum RBP-4 levels may be a useful marker for MetSyn and the measurement of serum RBP-4 levels is not difficult, it could allow clinicians and scientists to readily collect valuable information on metabolic complications in HIV-infected subjects receiving HAART.
Serum RBP-4 levels were significantly, positively correlated with the number of components of MetSyn presented, TG, waist circumference, WHR and BMI without adjustment. After adjustment for age and BMI, the significant correlation with serum RBP-4 levels was sustained for the number of components of MetSyn presented, TG and waist circumference. The total duration of HAART and known duration of HIV infection had no correlation with serum RBP-4 levels ( Table 2 ). Subjects that presented with 3 or 4 components of MetSyn demonstrated significantly higher serum RBP-4 levels than subjects that presented with none or only 1 component of MetSyn (Fig. 1) . In stepwise multivariate linear regression analysis, we identified the number of components of MetSyn and waist circumference as the variables most strongly associated with RBP-4 ( Table 2) .
Metabolic and body fat abnormalities are common sideeffects in HIV-infected subjects receiving HAART, and several reports have suggested that these subjects also involve an increased risk of CVD. 15, 16 Although the mechanism is not completely understood, adipocytokines such as adiponectin and leptin might contribute to the clinical features of this condition. 17 Adipose tissue is considered to be an endocrine organ, and the hormonal alterations caused by changes in body fat may play an important role in metabolic abnormalities in HIV-infected subjects receiving HAART. 17 Therefore, we investigated the relationship between serum levels of RBP-4, an adipocytokine, and MetSyn in HIV-infected subjects receiving HAART.
In this study, elevated serum RBP-4 levels were associat- 
